
Antonio Scalfari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6107522/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Smouldering multiple sclerosis: the â€~real MS'. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642110667.	3.5	72
2	Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool. Multiple Sclerosis Journal, 2021, 27, 1442-1450.	3.0	3
3	Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1007-1013.	1.9	22
4	Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patients. Current Opinion in Neurology, 2021, 34, 277-285.	3.6	6
5	MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Yes. Multiple Sclerosis Journal, 2021, 27, 1002-1004.	3.0	3
6	A novel prognostic score to assess the risk of progression in relapsingâ remitting multiple sclerosis patients. European Journal of Neurology, 2021, 28, 2503-2512.	3.3	14
7	Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis. Neurology, 2021, 97, e890-e901.	1.1	19
8	Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110576.	3.5	5
9	Prognostic information for people with MS: Impossible or inevitable?. Multiple Sclerosis Journal, 2020, 26, 771-773.	3.0	5
10	The <scp>CSF</scp> Profile Linked to Cortical Damage Predicts Multiple Sclerosis Activity. Annals of Neurology, 2020, 88, 562-573.	5.3	46
11	MS progression is predominantly driven by age-related mechanisms – YES. Multiple Sclerosis Journal, 2019, 25, 902-904.	3.0	11
12	The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. Neurology, 2018, 90, e2107-e2118.	1.1	82
13	Monoclonal Antibody Therapy and Long-term Outcomes in Multiple Sclerosis – The Challenge of Treatment Optimisation. European Neurological Review, 2018, 13, 78.	0.5	0
14	Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. The Cochrane Library, 2017, 4, CD012200.	2.8	20
15	Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome – NO. Multiple Sclerosis Journal, 2015, 21, 1371-1374.	3.0	2
16	Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients. PLoS ONE, 2015, 10, e0135428.	2.5	49
17	Onset of secondary progressive phase and long-term evolution of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 67-75.	1.9	224
18	Mortality in patients with multiple sclerosis. Neurology, 2013, 81, 184-192.	1.1	199

ANTONIO SCALFARI

#	Article	IF	CITATIONS
19	Early Relapses, Onset of Progression, and Late Outcome in Multiple Sclerosis. JAMA Neurology, 2013, 70, 214.	9.0	88
20	Combined MRI Lesions and Relapses as a Surrogate for Disability in MS. Neurology, 2012, 78, 1367-1367.	1.1	2
21	Reply to Oluf Anderson's Reply: Predicting a window of therapeutic opportunity in multiple sclerosis. Brain, 2011, 134, e175-e175.	7.6	0
22	Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach: Measuring disability in relapsing-remitting MS. Neurology, 2011, 76, 1025-1026.	1.1	5
23	The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain, 2010, 133, 1914-1929.	7.6	563
24	Clinical prognostic factors in multiple sclerosis: a natural history review. Nature Reviews Neurology, 2009, 5, 672-682.	10.1	138
25	Abnormal associative plasticity of the human motor cortex in writer's cramp. Brain, 2003, 126, 2586-2596.	7.6	353